Glenmark Pharma
Ticker > Company >

Glenmark Pharma share price

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK BSE: 532296 SECTOR: Pharmaceuticals & Drugs  255k   1k   224

1390.00
-5.25 (-0.38%)
BSE: 09 May 04:01 PM

Price Summary

Today's High

₹ 1412.65

Today's Low

₹ 1356.8

52 Week High

₹ 1830.05

52 Week Low

₹ 985.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 39225.91 Cr.

Enterprise Value

₹ 39754 Cr.

No. of Shares

28.22 Cr.

P/E

6.46

P/B

1.61

Face Value

₹ 1

Div. Yield

0.18 %

Book Value (TTM)

₹  863.21

CASH

₹ 129.15 Cr.

DEBT

₹ 657.24 Cr.

Promoter Holding

46.65 %

EPS (TTM)

₹  215.32

Sales Growth

-4.01%

ROE

25.3 %

ROCE

32.59%

Profit Growth

327.48 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glenmark Pharmaceuticals Ltd.

CANDID ALEX-P SYRUP SIBUTRIM GLINATE LEREZ VORTH-XT STRONAT ERDOZET DYCERIN FINTOP SIBET NITAZET-O ONABET ESOZ - D COLY-MONAS PALNOX AIRTEC-FB BORTRAC GEFTIB TAZRET EVERMIL GLUCAR ZINOX TACROZ FORTE FLEXILOR MIGNAR ASCORIL PLUS TACROZ

Index Presence

The company is present in 31 Indices.

NIFTYMIDCAP

NIFTY Midcap 100
53223.35
  -5.95000000000437 (-0.0111780541919626%)

NFT500MOM50

Nifty500 Momentum 50
48948.7
  -356.650000000001 (-0.72334949452747%)

NIFTYALPHA

Nifty Alpha 50
46487.3
  -200.049999999996 (-0.428488659133563%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
45290.75
  -149.050000000003 (-0.328016408522935%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
41288.55
  -394.5 (-0.946427864563648%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
40221.15
  96.25 (0.239875987229876%)

NT200ALP30

NIFTY200 Alpha 30
22982.25
  -75.3499999999985 (-0.326790299077084%)

NIFTY500

Nifty 500
21675.55
  -167.5 (-0.766834301986219%)

NIFTYPHARMA

Nifty Pharma
21071.75
  -43.2999999999993 (-0.205067001972525%)

NIFTYMIDCAP150

Nifty Midcap 150
19596.25
  4.45000000000073 (0.02271358425463%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17953.75
  -38.4500000000007 (-0.213703716054736%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16256.3
  -87.6500000000015 (-0.536284068416759%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15122.65
  -72.3500000000004 (-0.476143468246137%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14882.4
  -96.8000000000011 (-0.646229438154244%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
14082.05
  -34.1000000000004 (-0.241567282863953%)

NIFTYHEALTH

Nifty Healthcare Index
13672.8
  -23.9500000000007 (-0.174858999397676%)

NIFTY200

Nifty 200
13217.7
  -109.049999999999 (-0.81827902526872%)

NFT500EQUAL

Nifty 500 Equal Weight
12786.55
  -50.1000000000004 (-0.390288743558487%)

NIFTYTOTALMCAP

Nifty Total Market index
12168.05
  -91.1000000000004 (-0.743118405435939%)

MIDCAP

S&P Bse Mid Cap
42111.5
  -42.9700000000012 (-0.101934622828848%)

BSE HC

S&P Bse Healthcare
41222.6
  -65.3400000000038 (-0.158254444275985%)

BSE500

S&P Bse 500
34105.3
  -234.399999999994 (-0.682591868886429%)

MID150

S&P Bse 150 MidCap
14663.81
  2.97999999999956 (0.0203262707500151%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
10904.46
  -18.8900000000012 (-0.17293229641091%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

LMI250

S&P Bse 250 LargeMidCap
10199.68
  -71.5399999999991 (-0.696509275431734%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

BSE1000

Bse 1000
10119.33
  -66.2999999999993 (-0.650917027223641%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SPBSMOIP

S&P Bse Momentum
2012.25
  -8.44000000000005 (-0.41767910961108%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-4.01%
3 Year1.4%
5 Year4.59%

Profit Growth

1 Year327.48%
3 Year46.32%
5 Year26.08%

ROE%

1 Year25.3%
3 Year14.99%
5 Year13.5%

ROCE %

1 Year32.59%
3 Year18.14%
5 Year15.64%

Debt/Equity

0.0286

Price to Cash Flow

-79.17

Interest Cover Ratio

26.2634

CFO/PAT (5 Yr. Avg.)

0.440963595563448

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 46.65 0.00
Dec 2024 46.65 0.00
Sep 2024 46.65 0.00
Jun 2024 46.65 0.00
Mar 2024 46.64 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 46.3215135497746% for the Past 3 years.
  • The company has significantly decreased its debt by 2499.164 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 26.2634.
  • Company’s PEG ratio is 0.0197144635710669.
  • The company has an efficient Cash Conversion Cycle of -137.5008 days.

 Limitations

  • The company has shown a poor revenue growth of 1.40367877643066% for the Past 3 years.
  • Company has negative cash flow from operations of -495.45.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 1365.1 2148.22 2329.54 2636.1 2251.28
Total Expenditure 1549.36 1650.78 1698.44 1857.47 1757.35
Operating Profit -184.27 497.45 631.1 778.63 493.93
Other Income 258.82 786.27 55.65 83.08 129.19
Interest 73.6 83.39 15.35 11.8 8.46
Depreciation 51.16 52.4 53.09 54.85 55.16
Exceptional Items -25.28 5146.91 0 0 0
Profit Before Tax -75.5 6294.85 618.31 795.06 559.49
Tax -55.09 1681.15 164.58 200 145.69
Profit After Tax -20.41 4613.7 453.73 595.06 413.8
Adjusted EPS (Rs) -0.72 163.5 16.08 21.09 14.66

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 6712.63 7567.93 8141.58 8220.66 7891.12
Total Expenditure 5408.4 5677.59 6453.36 6747.9 6649.46
Operating Profit 1304.23 1890.34 1688.22 1472.77 1241.66
Other Income 606.79 396.24 614.63 985.94 1168.02
Interest 256.39 265.9 236.04 206.82 277.11
Depreciation 138.54 150.82 159.7 184.15 202.16
Exceptional Items 18.55 73.89 430.33 -495.87 5070.33
Profit Before Tax 1534.64 1943.76 2337.45 1571.87 7000.75
Tax 180.1 294.31 339.66 363.11 1833.46
Net Profit 1354.55 1649.45 1997.79 1208.77 5167.29
Adjusted EPS (Rs.) 48 58.46 70.8 42.84 183.11

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 28.22 28.22 28.22 28.22 28.22
Total Reserves 13198.05 14781.29 16710.37 17849.25 22942.4
Borrowings 3131.17 3112.58 2571.74 2660.82 0
Other N/C liabilities 389.35 1150.51 1412.85 2394.32 3286.93
Current liabilities 2991.54 3934.34 4896.21 3991.95 5152.18
Total Liabilities 19738.33 23006.93 25619.39 26924.55 31409.72
Assets
Net Block 1611.95 1722.49 1752.33 1745.94 1756.25
Capital WIP 152.5 93.31 101.17 159.07 175.5
Intangible WIP 47.52 38.09 7.87 13.27 22.17
Investments 4713.93 6989.95 8559.39 10332.71 12964.79
Loans & Advances 8182.74 7818.27 9335.01 9934.57 10940.59
Other N/C Assets 2.78 4.72 5.55 3.63 6.18
Current Assets 5026.92 6340.11 5858.08 4735.35 5544.26
Total Assets 19738.33 23006.93 25619.39 26924.55 31409.72
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1534.64 1943.76 2337.45 1571.87 7000.75
Adjustment -107.18 235.11 -617.5 122.48 -5884.79
Changes in Assets & Liabilities 491.01 -599.61 -113.17 196.13 -740.31
Tax Paid -339.35 -335.84 -390.72 -416.42 -871.1
Operating Cash Flow 1579.12 1243.42 1216.07 1474.06 -495.45
Investing Cash Flow -1607.41 -1235.19 -897.02 -431.52 3197.17
Financing Cash Flow -139.42 -80.79 -305.12 -978.5 -2666.45
Net Cash Flow -167.71 -72.57 13.93 64.05 35.27

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 46.64 46.65 46.65 46.65 46.65
blanche elizabeth saldanh... 0.39 0.39 0.39 0.39 0.39
cherylann maria pinto 0.27 0.27 0.27 0.27 0.27
glenn mario saldanha 0.35 0.35 0.35 0.35 0.35
neha saldanha 0.01 0.01 0.01 0.01 0.01
robin joseph pinto 0.18 0.18 0.18 0.18 0.18
saldanha family trust 45.45 45.45 45.45 45.45 45.45
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 53.36 53.35 53.35 53.35 53.35
3p india equity fund 1 - - - 1.02 1.02
ashish dhawan 2.55 2.55 2.55 1.88 1.77
ellipsis partners llc 1.68 1.68 1.31 1.17 1.11
government pension fund g... 3.14 3.25 3.25 3.25 3.25
hdfc mutual fund - hdfc n... - - - - 4.27
invesco india midcap fund... - - 1.07 - 1.41
investor education and pr... - 0.09 0.09 0.09 0.09
mirae asset arbitrage fun... - - - - 3.53
smallcap world fund, inc 3.47 3.13 3.10 3.38 3.21
aditya birla sun life tru... 2.06 1.50 1.15 1.16 -
hdfc mutual fund - hdfc m... 2.54 3.63 - 3.46 -
invesco india manufacturi... - - - 1.17 -
mirae asset large & midca... - - - 3.55 -
hdfc mutual fund-hdfc arb... - - 3.42 - -
mirae asset elss tax save... - - 2.80 - -
icici prudential mnc fund... 1.23 - - - -
investor education and pr... 0.09 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Glenmark Pharmaceuticals’ arm to launch generic Adderall tablets 17 Apr, 12:21 PM Glenmark Pharmaceuticals’ arm recalls over 25 products in US market 14 Apr, 11:16 AM Glenmark’s US arm recalling 8,160 bottles of chlorpromazine hydrochloride tablets in US 11 Apr, 3:08 PM Glenmark Pharmaceuticals informs about appointment of senior management personnel 7 Apr, 9:32 AM Glenmark Pharmaceuticals informs about press release 1 Apr, 11:46 AM Glenmark’s US arm launches Vancomycin Hydrochloride for injection USP 1 Apr, 10:07 AM Glenmark Pharmaceuticals informs about disclosure 29 Mar, 11:57 AM Glenmark Pharmaceuticals informs about newspaper advertisement 27 Mar, 5:22 PM Glenmark’s US arm gets USFDA’s approval for Olopatadine Hydrochloride Ophthalmic Solution 21 Mar, 9:35 AM Glenmark Pharmaceuticals launches Empagliflozin in India 12 Mar, 1:00 PM Glenmark Pharmaceuticals informs about media release 12 Mar, 12:17 PM Glenmark Pharmaceuticals’ arm launches Polyethylene Glycol 3350 10 Mar, 9:35 AM Glenmark Pharmaceuticals informs about media release 10 Mar, 9:22 AM Glenmark Pharmaceuticals’ US arm recalls around 14.76 lakh bottles of Atomoxetine Capsules 3 Mar, 10:25 AM Glenmark Pharmaceuticals informs about media release 3 Mar, 9:29 AM Glenmark Pharmaceuticals’ arm acquires, launches Acetylcysteine Injection 3 Mar, 9:22 AM Glenmark Pharmaceutical informs about media release 27 Feb, 9:38 AM Glenmark Pharmaceuticals’ US arm launches Epinephrine Injection 27 Feb, 9:08 AM Glenmark Pharmaceuticals turns black in Q3 17 Feb, 4:41 PM Glenmark Pharmaceuticals informs about conference call 17 Feb, 2:08 PM Glenmark Pharma - Quaterly Results 14 Feb, 6:19 PM Glenmark Pharma - Quaterly Results 14 Feb, 6:19 PM Glenmark Pharma - Quaterly Results 14 Feb, 6:19 PM Glenmark Pharmaceuticals informs about media release 14 Feb, 10:36 AM Glenmark Pharmaceuticals’ US arm launches Latanoprost Ophthalmic Solution 14 Feb, 10:30 AM Glenmark Pharmaceuticals informs about media release 12 Feb, 12:55 PM Glenmark Pharmaceuticals’ US arm launches Clindamycin Phosphate Foam, 1% 12 Feb, 10:08 AM Glenmark Pharmaceuticals informs about press release 10 Feb, 4:59 PM Glenmark Pharmaceuticals’ US arm launches Phytonadione Injectable Emulsion 21 Jan, 9:58 AM Glenmark Pharmaceuticals informs about media release 21 Jan, 9:26 AM Glenmark’s US arm recalling affected lot of Diltiazem Hydrochloride extended-release capsules 16 Dec, 9:58 AM Glenmark Pharmaceuticals informs about media release 16 Dec, 9:50 AM Glenmark Pharmaceuticals’ US arm launches Lacosamide Oral Solution 16 Dec, 9:14 AM Glenmark Pharmaceuticals informs about press release 10 Dec, 9:55 AM Glenmark Pharmaceuticals submits Press Release 27 Nov, 10:04 AM Glenmark Pharmaceuticals’ US arm launches Travoprost Ophthalmic Solution 27 Nov, 9:59 AM Glenmark Pharmaceuticals informs about audio recording of earnings call 18 Nov, 5:24 PM Glenmark Pharma - Quaterly Results 14 Nov, 6:37 PM Glenmark Pharma - Quaterly Results 14 Nov, 6:37 PM Glenmark Pharma - Quaterly Results 14 Nov, 6:37 PM Glenmark Pharmaceuticals informs about media release 6 Nov, 9:55 AM Glenmark Pharmaceuticals informs about board meeting 30 Oct, 5:35 PM Glenmark Pharmaceuticals informs about closure of trading window 30 Oct, 5:31 PM Glenmark’s US arm recalls bottles of Ryaltris Nasal Spray 14 Oct, 12:45 PM USFDA completes GMP inspection at Glenmark Pharma’s facility at Aurangabad 21 Sep, 4:01 PM Glenmark Pharmaceuticals informs about disclosure 21 Sep, 2:22 PM Glenmark’s US arm recalling bottles of Indomethacin Extended-Release Capsules 27 Aug, 12:48 PM Glenmark Pharmaceuticals informs about media release 19 Aug, 9:53 AM Glenmark Pharmaceuticals’ arm launches Olopatadine Hydrochloride Ophthalmic Solution 19 Aug, 9:44 AM Glenmark Pharmaceuticals reports 9-fold jump in Q1 consolidated net profit 16 Aug, 2:30 PM

Glenmark Pharma Stock Price Analysis and Quick Research Report. Is Glenmark Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glenmark Pharma and its performance over the period of time. Glenmark Pharma stock price today is Rs 1398.2.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Glenmark Pharma cash from the operating activity was Rs -495.45 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glenmark Pharma has a Debt to Equity ratio of 0.0286 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glenmark Pharma , the EPS growth was 327.4537 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glenmark Pharma has OPM of 15.734942027867 % which is a good sign for profitability.
     
  • ROE: Glenmark Pharma have a healthy ROE of 25.3032 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Glenmark Pharma is Rs 1398.2. One can use valuation calculators of ticker to know if Glenmark Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Glenmark Pharma

Glenmark Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the Glenmark Pharmaceuticals Ltd stock analysis page tailored for college student stock investors seeking comprehensive insights. In this section, we will delve into various aspects of Glenmark Pharmaceuticals Ltd, including its share price, balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders. Our objective is to equip you with valuable information to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Share Price Analysis 

Evaluate the share price of Glenmark Pharmaceuticals Ltd to gauge its market performance. Utilize Ticker pre-built screening tools to assess the current stock price and compare it with industry peers. Leverage our platform's market trends and indicators to aid your analysis as a college student stock investor seeking to assess the potential of this stock.

Glenmark Pharmaceuticals Ltd Balance Sheet Evaluation 

Evaluate the balance sheet of Glenmark Pharmaceuticals Ltd to understand the company's financial stability and performance. Leverage our premium features, including DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, to calculate the fair value based on the balance sheet. These tools provide a comprehensive view of the company's financials, empowering you to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Annual Report Review 

Access the annual reports of Glenmark Pharmaceuticals Ltd for valuable insights into the company's performance, strategies, and future prospects. Downloadable versions of the annual reports are available on Ticker, facilitating thorough analysis. College student stock investors will find these reports invaluable for understanding the company's long-term vision and growth trajectory.

Glenmark Pharmaceuticals Ltd Dividend Analysis 

Evaluate the dividend policy and history of Glenmark Pharmaceuticals Ltd. Ticker pre-built screening tools assist in analyzing the company's dividend payment history and potential. Monitor the dividend yield to assess the income potential associated with this stock. Dividend analysis is essential for college student stock investors, as it provides insights into how the company rewards its shareholders.

Glenmark Pharmaceuticals Ltd Quarterly Results Examination 

Analyze the quarterly financial results of Glenmark Pharmaceuticals Ltd to evaluate its performance and growth trends. Our premium features, such as DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, facilitate fair value calculations based on the quarterly results. This analysis delves into the company's revenue, expenses, and profitability.

Glenmark Pharmaceuticals Ltd Stock Price Monitoring 

Stay updated on the stock price of Glenmark Pharmaceuticals Ltd and track market trends. Our platform provides a detailed stock price chart, enabling historical data analysis and identification of patterns and trends. Understanding the stock's performance over time is crucial for college student stock investors seeking to make well-informed investment decisions.

Glenmark Pharmaceuticals Ltd Price Chart Analysis 

Analyze the price chart of Glenmark Pharmaceuticals Ltd to identify patterns and trends that can influence investment decisions. Ticker user-friendly interface allows for visual exploration of the stock's historical performance, enhancing understanding of market dynamics. Utilize this information to identify potential entry and exit points.

Glenmark Pharmaceuticals Ltd News Updates 

Stay updated with the latest news articles about Glenmark Pharmaceuticals Ltd. Ticker dedicated news section on the website offers valuable information on the company's recent developments, market trends, and industry updates. Staying informed is pivotal for college student stock investors looking to make sound investment decisions amid the dynamic market landscape.

Glenmark Pharmaceuticals Ltd Conference Call Transcripts 

Access conference call transcripts of Glenmark Pharmaceuticals Ltd to gain insights into the company's operations, strategies, and future plans. These transcripts comprehensively outline key discussions and announcements made during the company's conference calls. Utilize this information to gain a deeper understanding of the company's direction and prospects.

Glenmark Pharmaceuticals Ltd Investor Presentations 

Explore investor presentations of Glenmark Pharmaceuticals Ltd to obtain valuable insights into the company's growth potential and investment opportunities. These presentations provide an overview of the company's value proposition, strategies, and financial performance. Analyzing investor presentations can offer college student stock investors a better understanding of the company's vision and plans.

Glenmark Pharmaceuticals Ltd Promoters & Shareholders 

Understand the ownership structure of Glenmark Pharmaceuticals Ltd by reviewing its key promoters and major shareholders. Gain insights into ownership concentration and potential alignment of interests. Ticker provides detailed information about the company's promoters and major shareholders, enabling informed investment decisions and understanding of the key stakeholders driving the company's growth.

Glenmark Pharmaceuticals Ltd ROCE

Glenmark Pharmaceuticals Ltd's Return on Capital Employed (ROCE) is a vital financial metric that evaluates the company's profitability and efficiency in utilizing its capital investments. Our stock analysis page provides comprehensive ROCE data for Glenmark Pharmaceuticals Ltd, allowing investors to assess the company's ability to generate returns from the capital employed. By analyzing this ratio, investors can gain insights into the company’s financial performance. Access the detailed ROCE information for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd EBITDA

Glenmark Pharmaceuticals Ltd's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a key measure for evaluating the company's operational performance and profitability. Our stock analysis page offers comprehensive EBITDA data for Glenmark Pharmaceuticals Ltd, enabling investors to assess the company's core earnings and financial health. Access the detailed EBITDA figures for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd DPS

Glenmark Pharmaceuticals Ltd's Dividends Per Share (DPS) indicate the portion of profits distributed to shareholders as dividends. Monitoring DPS is essential for investors seeking a consistent income from dividends. Our stock analysis page features the DPS data for Glenmark Pharmaceuticals Ltd, enabling investors to track the company's dividend history and payout ratio. Access the detailed DPS information for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) is a fundamental financial metric that measures Glenmark Pharmaceuticals Ltd's profitability on a per-share basis. Our stock analysis page provides detailed EPS information for Glenmark Pharmaceuticals Ltd, allowing investors to assess the company's earnings performance and growth potential. Access the comprehensive EPS figures for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page to make informed investment decisions. 

Glenmark Pharmaceuticals Share Capital Stability

Glenmark Pharmaceuticals has shown a constant Share Capital figure at Rs 28.22 Cr from March 2020 to March 2024, indicating a stable equity structure without any dilution to the shareholders' value during this period.

Glenmark Pharmaceuticals Reserves Growth

The Total Reserves of Glenmark Pharmaceuticals have seen a significant rise from Rs 13,198.05 Cr in March 2020 to Rs 22,942.40 Cr by March 2024. This robust increase in reserves underscores the company's solid financial health and its capability to support future growth.

Reducing Debt in Glenmark Pharmaceuticals' Financials

A notable aspect of Glenmark Pharmaceuticals' balance sheet is the reduction of Borrowings to zero by March 2024, down from Rs 3,131.17 Cr in March 2020. This debt clearance is a positive sign, reflecting the company's strong focus on achieving a debt-free status, enhancing its financial resilience.

Investments and Asset Growth at Glenmark Pharmaceuticals

Glenmark Pharmaceuticals' Investments have nearly tripled, moving from Rs 4,713.93 Cr in March 2020 to Rs 12,964.79 Cr by March 2024. Additionally, the consistent growth in Assets, from Rs 19,738.33 Cr in March 2020 to Rs 31,409.72 Cr in March 2024, highlights the company's aggressive expansion and reinvestment in its future.

This data is an analysis for the Standalone Balance sheet of Glenmark Pharmaceuticals. Investors looking into the pharmaceutical sector can also explore broader market trends on NSE/BSE indices, upcoming IPOs, or sectoral analyses for a comprehensive investment strategy.

Read More
X